Casey Lynch
Director/Board Member at LONGBOARD PHARMACEUTICALS, INC.
Net worth: - $ as of 2024-04-29
Profile
Casey Crawford Lynch founded Aspira Biosystems, Inc. in 1999, where she worked as President & Chief Executive Officer from 1999 to 2004, Neuroinsights LLC in 2004, where she worked as Managing Director from 2004 to 2015, Quince Therapeutics, Inc. in 2012, where she worked as Chairman, President & Chief Executive Officer from 2018 to 2022, Neurotechnology Industry Organization in 2005, where she worked as Director from 2005 to 2018, and Sonoma Bioventures in 2022, where she is working as Managing Partner from 2022.
Ms. Lynch also founded Lighthouse Pharmaceuticals, Inc., where she worked as Chief Executive Officer.
Ms. Lynch also currently works at Longboard Pharmaceuticals, Inc., as Independent Director from 2021 and Alzheimers Drug Discovery Foundation, as Member-Business Review Board.
Ms. Lynch also formerly worked at California Life Sciences Association, as Director from 2019 to 2021.
Ms. Lynch received her undergraduate degree from the University of California, Los Angeles and graduate degree from The University of California, San Francisco.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2024-03-14 | 0 ( -.--% ) | - $ | 2024-04-29 |
Casey Lynch active positions
Companies | Position | Start |
---|---|---|
LONGBOARD PHARMACEUTICALS, INC. | Director/Board Member | 2021-01-31 |
Lighthouse Pharmaceuticals, Inc.
Lighthouse Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Lighthouse Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that specializes in precision medicine approaches to address major unmet medical needs. The private company is based in San Francisco, CA. The company's expertise lies in small molecule protease inhibition. Lighthouse's lead program, LHP588, is a phase 2b ready orally bioavailable small molecule that targets a specific infectious pathogen, Porphyromonas gingivalis. This pathogen is associated with chronic degenerative and inflammatory disorders such as dementia, periodontal disease, atherosclerosis, and orodigestive cancers. Lighthouse Pharmaceuticals was founded in 2022 by Casey Crawford Lynch, who has been the CEO since 2022. | Chief Executive Officer | - |
Sonoma Bioventures | Founder | 2022-01-31 |
Alzheimers Drug Discovery Foundation
Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr. | Corporate Officer/Principal | - |
Former positions of Casey Lynch
Companies | Position | End |
---|---|---|
QUINCE THERAPEUTICS, INC. | Chief Executive Officer | 2022-01-31 |
California Life Sciences Association
California Life Sciences Association Miscellaneous Commercial ServicesCommercial Services California Life Sciences Association (CLSA) is the largest and most influential life sciences advocacy and business leadership organization in California. The non-profit company is based in South San Francisco, CA, and has offices in other locations as well. The company works closely with industry, government, academia, and others to shape public policy, improve access to innovative technologies, and grow California's life sciences economy. CLSA serves biotechnology, pharmaceutical, medical device, and diagnostics companies, research universities and institutes, investors, and service providers throughout the state. Mike Guerra has been the CEO of the company since 2019. | Director/Board Member | 2020-12-31 |
Neurotechnology Industry Organization | Founder | 2018-08-31 |
Neuroinsights LLC
Neuroinsights LLC Financial ConglomeratesFinance Neuroinsights LLC provides consultation and advice on investing in the neurotech industry. The company was founded by Casey and Zach Lynch and is headquartered in San Francisco, CA. | Founder | 2014-12-31 |
Aspira Biosystems, Inc.
Aspira Biosystems, Inc. Information Technology ServicesTechnology Services Part of Nanomune Technologies, Inc., Aspira Biosystems, Inc. develops technology that enables the capture of targeted proteins. The company is based in San Francisco, CA. The company was founded by Casey Crawford Lynch. Aspira Biosystems was acquired by Nanomune Technologies, Inc. on July 20, 2004. | Chief Executive Officer | 2003-12-31 |
Training of Casey Lynch
University of California, Los Angeles | Undergraduate Degree |
The University of California, San Francisco | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
QUINCE THERAPEUTICS, INC. | Health Technology |
LONGBOARD PHARMACEUTICALS, INC. | Health Technology |
Private companies | 7 |
---|---|
Aspira Biosystems, Inc.
Aspira Biosystems, Inc. Information Technology ServicesTechnology Services Part of Nanomune Technologies, Inc., Aspira Biosystems, Inc. develops technology that enables the capture of targeted proteins. The company is based in San Francisco, CA. The company was founded by Casey Crawford Lynch. Aspira Biosystems was acquired by Nanomune Technologies, Inc. on July 20, 2004. | Technology Services |
Alzheimers Drug Discovery Foundation
Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr. | Health Technology |
Neuroinsights LLC
Neuroinsights LLC Financial ConglomeratesFinance Neuroinsights LLC provides consultation and advice on investing in the neurotech industry. The company was founded by Casey and Zach Lynch and is headquartered in San Francisco, CA. | Finance |
California Life Sciences Association
California Life Sciences Association Miscellaneous Commercial ServicesCommercial Services California Life Sciences Association (CLSA) is the largest and most influential life sciences advocacy and business leadership organization in California. The non-profit company is based in South San Francisco, CA, and has offices in other locations as well. The company works closely with industry, government, academia, and others to shape public policy, improve access to innovative technologies, and grow California's life sciences economy. CLSA serves biotechnology, pharmaceutical, medical device, and diagnostics companies, research universities and institutes, investors, and service providers throughout the state. Mike Guerra has been the CEO of the company since 2019. | Commercial Services |
Neurotechnology Industry Organization | |
Sonoma Bioventures | |
Lighthouse Pharmaceuticals, Inc.
Lighthouse Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Lighthouse Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that specializes in precision medicine approaches to address major unmet medical needs. The private company is based in San Francisco, CA. The company's expertise lies in small molecule protease inhibition. Lighthouse's lead program, LHP588, is a phase 2b ready orally bioavailable small molecule that targets a specific infectious pathogen, Porphyromonas gingivalis. This pathogen is associated with chronic degenerative and inflammatory disorders such as dementia, periodontal disease, atherosclerosis, and orodigestive cancers. Lighthouse Pharmaceuticals was founded in 2022 by Casey Crawford Lynch, who has been the CEO since 2022. | Commercial Services |
- Stock Market
- Insiders
- Casey Lynch